Core Viewpoint - Gilead Sciences, Inc. is expected to report its fourth-quarter and full-year 2024 results on February 11, with sales and earnings estimates at $7.06 billion and $1.66 per share respectively [1] Earnings Performance - Gilead has beaten earnings estimates in three of the last four quarters, with an average surprise of 15.46% [2] Earnings Prediction - The model predicts an earnings beat for Gilead, supported by a positive Earnings ESP of +1.70% and a Zacks Rank of 3 (Hold) [3] Factors Influencing Q4 Results - Gilead's HIV franchise, particularly Biktarvy and Descovy, is expected to drive sales, with Biktarvy sales estimated at $3.46 billion and Descovy at $574 million [4][5] - The Liver Disease portfolio is likely to benefit from increased demand for viral hepatitis medicines and the launch of Livdelzi for primary biliary cholangitis [5][6] Sales Estimates - Sales for Cell Therapy products are estimated at $480 million, with a potential decrease due to competitive pressures [7] - Trodelvy sales are estimated at $282 million, with potential impacts from market conditions [8][9] Recent Developments - Trodelvy received Breakthrough Therapy Designation from the FDA for extensive-stage small cell lung cancer [10] - The European Medicines Agency recommended seladelpar for PBC treatment, with a final decision expected in Q1 2025 [11] Stock Performance - Gilead's shares have increased by 31.8% over the past year, contrasting with a 6.3% decline in the industry [14]

Eversource Energy (ES) is scheduled to release fourth-quarter 2024 results on Feb. 11, after market close. The company delivered an earnings surprise of 8.7% in the last reported quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Let’s discuss the factors that are likely to be reflected in the upcoming quarterly results.Key Factors That Might Have Impacted ES' Q4 PerformanceThe bottom line is expected to have benefited from the completed sale of its 50% interest in the 132-megawatt ...

BP plc (BP) , the British oil and gas giant, has decided to hit the brakes on the production of renewable fuels at the site of its previous Kwinana oil refinery in Western Australia. The move is believed to be part of the company’s cost-cutting initiatives.BP had plans to construct a biofuels project in Australia, known as Kwinana Renewable Fuels (“KRF”), alongside a green hydrogen plant named H2Kwinana. The Kwinana refinery was once Australia’s largest oil refinery, with a capacity of 146,000 barrels per d ...

Take-Two Interactive Software Inc TTWO reported upbeat third-quarter financial earnings after the market close on Thursday.Take-Two reported third-quarter revenue of $1.37 billion, missing analyst estimates of $1.39 billion, according to Benzinga Pro. The video game publisher reported third-quarter adjusted earnings of 72 cents per share, beating analyst estimates of 57 cents per share.Total net bookings grew 3% year-over-year. Net Bookings from recurrent consumer spending grew 9% year-over-year and account ...

Palantir Technologies Inc. (NASDAQ: PLTR ) has delivered a stunning performance in the last year, with shares of the software analytics company surging more than 500%. Shares soared to a new all-time high of $106.91 afterAnalyst’s Disclosure: I/we have a beneficial long position in the shares of CRM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no bus ...

One company that I have been rather drawn to since it was spun off from its parent is Crane NXT (NYSE: CXT ). If you're not familiar with the business, it really operates two separate divisions that focusCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, a ...

Shares of the United States' No. 3 energy drink maker Celsius (CELH 0.41%) dropped 11% this week as of 2:30 p.m. ET Friday, according to data provided by S&P Global Market Intelligence.While there wasn't one specific catalyst that sent the company's stock downward, a number of lingering worries continue to weigh on Celsius and its deflated share price.Is Celsius down for good?Just 18 months ago, Celsius was growing sales by triple digits, and its stock would go on to reach $90 per share. As of its latest qu ...

Key TakeawaysSupermicro shares have surged ahead of a second-quarter update expected Tuesday on hopes the firm will be able to submit its delayed filings and preserve its public listing.The company also said this week it is ramping to full production availability of its AI data center solutions platform.Supermicro has until Feb. 25 to submit its delayed annual report from its fiscal year ended last June, or it could face delisting by the Nasdaq. Super Micro Computer (SMCI) shares surged Friday, extending g ...

Aptiv PLC APTV reported better-than-expected financial results and issued strong guidance on Thursday.The company posted quarterly revenue of $4.91 billion, versus estimates of $4.89 billion. Adjusted earnings came in at $1.75 per share, versus estimates of $1.65 per share."Looking ahead, as we navigate a dynamic market environment, we will remain focused on enabling our customers as they transition to a more feature-rich, software-defined future," said Kevin Clark, chairman and CEO of Aptiv."This year also ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SOFI, PYPL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether ...